rosiglitazone has been researched along with Adenoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Gruszka, A; Kunert-Radek, J; Pawlikowski, M; Radek, M; Winczyk, K; Ławnicka, H | 1 |
| Belinsky, SA; Damiani, LA; Do, KC; Grimes, MJ; Klinge, DM; Lyon, CM; March, TH; Stidley, CA; Thomas, CL | 1 |
| Acerbi, G; Bartalena, L; Bogazzi, F; Brogioni, S; Cecchetti, D; Cosci, C; Gasperi, M; Guida, C; Martino, E; Raggi, F; Russo, D; Ultimieri, F; Vanacore, R; Viacava, P | 1 |
| Bonner, SE; Emery, MN; Galloway, M; Grossman, AB; Korbonits, M; Leontiou, C; Merulli, C; Musat, M; Nanzer, AM; Nikookam, K; Powell, M | 1 |
| Gradiser, M; Matovinovic, M; Vrkljan, M | 1 |
| Akin, F; Bastemir, M; Yaylali, GF | 1 |
| Ebrahimsade, S; Eckhardt, J; Jäkel, J; Moll, R; Müller, R; Müller-Brüsselbach, S; Peters, JM; Rapp, UR | 1 |
1 trial(s) available for rosiglitazone and Adenoma
| Article | Year |
|---|---|
The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Male; Middle Aged; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2007 |
7 other study(ies) available for rosiglitazone and Adenoma
| Article | Year |
|---|---|
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Topics: Acromegaly; Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2009 |
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.
Topics: Adenoma; Animals; Antioxidants; Cell Line, Tumor; Disease Progression; Female; Histone Deacetylases; Humans; Hypoglycemic Agents; Immunohistochemistry; Lung Neoplasms; Mice; Neoplasm Invasiveness; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Human Growth Hormone; Humans; Ligands; Mice; Mice, Nude; NIH 3T3 Cells; Pituitary Neoplasms; Promoter Regions, Genetic; Rats; Rats, Inbred WF; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Humans; Immunohistochemistry; Middle Aged; Molecular Sequence Data; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Pituitary Neoplasms; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2006 |
Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Rosiglitazone; Thiazolidinediones | 2007 |
Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene.
Topics: Adenoma; Animals; Gene Expression Regulation, Neoplastic; Genotype; Hypoglycemic Agents; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; PPAR delta; PPAR-beta; Proto-Oncogene Proteins c-raf; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transgenes | 2007 |